COGT - CIK 0001622229
Cogent Biosciences, Inc. (COGT) reported net income of -$328.94M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$328.94M | -28.6% |
| FY 2024 | -$255.86M | -33.0% |
| FY 2023 | -$192.41M | -37.2% |
| FY 2022 | -$140.24M | -94.0% |
| FY 2021 | -$72.27M | +3.4% |
| FY 2020 | -$74.81M | -135.0% |
| FY 2019 | -$31.83M | +7.8% |
| FY 2018 | -$34.53M | -35.5% |
| FY 2017 |
Cogent Biosciences, Inc. (COGT) reported net income of -$328.94M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Cogent Biosciences, Inc.'s net income declined from -$25.49M to -$328.94M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$25.49M |
| - |